Kailera Therapeutics, Inc. (KLRA), a clinical-stage biotechnology company, on Friday announced the pricing of its initial public offering of 39.06 million shares of stock at $16 per share.
The offering is expected to raise gross proceeds of approximately $625 million, before underwriting discounts and expenses.
The company has granted underwriters a 30-day option to purchase up to an additional 5.86 million shares at the offering price, which could increase total proceeds if exercised.
Shares are expected to begin trading on the Nasdaq Global Select Market on April 17, 2026, under the ticker symbol "KLRA," with the offering anticipated to close on April 20, 2026, subject to customary closing conditions.
For comments and feedback contact: editorial@rttnews.com
Business News
April 17, 2026 15:29 ET The ongoing conflict in the Middle East continues to raise concerns for policymakers who worry about the impact of the supply shock and high energy prices on the real economy. Producer price data and various survey results on the housing market were the main news from the U.S. this week. In Europe, industrial production data for the euro area gained attention. GDP figures out of China and the policy move by the Singapore central bank were in focus in Asia.